ArticleScientific reports2025
Regulation of divergent epithelial-to-mesenchymal transition responses via the CDK4/6-USP51 pathway through ZEB1 protein stabilization.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physicochemical features of intrinsically disordered regions predict DNA-demethylation-promoting activity of transcription factors.Epigenetics & chromatin · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Epithelial-to-mesenchymal transition (EMT) is a cellular process important for numerous developmental processes, wound healing and cancer progression. In the context of heterogenous nature of cancer, EMT occurs at the forefront of tumor invasion, although the precise molecular mechanisms governing its spatial dynamics remain unclear. This study aimed to explore the diverse responses to EMT in monolayer cell cultures of MCF10A epithelial cell with induction of Zinc-finger E-box binding homeobox 1 (ZEB1), an EMT-inducing transcription factor. ZEB1-induced MCF10A cells exhibited EMT in space- and cell density-dependent manner. The expression of ZEB1 was modulated by the ubiquitin-proteasome pathway. We found that CDK4/6 and USP51 enhanced ZEB1 protein stability via deubiquitination. Moreover, suppressing USP51 and CDK4/6 activity attenuated cell migration, a characteristic of the mesenchymal phenotype, in ZEB1-induced MCF10A cells. Finally, we demonstrated that CDK4/6 kinase activity is important for cell migration as well as stabilizing ZEB1 in the mesenchymal breast cancer cell line MDA-MB-231. These insights could pave the way for developing more targeted and effective therapies targeting at ZEB1 and EMT in advanced cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.